RELIEVE: A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Sep 28, 2026 - P3 | N=180 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • CNS Disorders • Immunology • Myasthenia Gravis
|